FORTE

FORE Biotherapeutics to Present Promising New Data from Phase 1/2a Trial Evaluating Plixorafenib (FORE8394) in Patients With BRAF-Altered Advanced Solid and Central Nervous System Tumors at ASCO 2023

Retrieved on: 
Friday, May 26, 2023
Oncology, Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, University, PRS, PD, Shepherd, CRC, AE, Diarrhea, Neoplasm, Safety, Primary central nervous system lymphoma, DOR, Aes, MAPK, CYP3A, BRAF, Doctor of Philosophy, CNS, Associate, Glioblastoma, ASCO, V600, Malignancy, Neuro, American Society of Clinical Oncology, HIV disease progression rates, MD, Patient, Agency, Colorectal cancer, FORTE, Cancer, Annual general meeting, Memorial Sloan Kettering Cancer Center, Nausea, Orphan, Cobicistat, Ovarian cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Fasting, ORR, Food, Fatigue, Disease, Pharmaceutical industry, Medical imaging, Vaccine, Phosphorus

The results demonstrate promising single-agent activity against BRAF-altered tumors, including primary central nervous system (CNS) tumors, and will be featured in presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 2-6, 2023, in Chicago, IL.

Key Points: 
  • The results demonstrate promising single-agent activity against BRAF-altered tumors, including primary central nervous system (CNS) tumors, and will be featured in presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 2-6, 2023, in Chicago, IL.
  • “The updated data from our Phase 1/2a study further reinforces plixorafenib’s differentiated clinical profile,” said Stacie Shepherd, MD, PhD, and Chief Medical Officer of FORE.
  • “Plixorafenib has demonstrated both promising antitumor activity with durable responses and favorable tolerability as a single agent in patients with advanced BRAF-altered tumors.
  • Details for the ASCO 2023 presentations are as follows:
    Title: Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study

FORE Biotherapeutics Receives FDA Orphan Drug Designation for FORE8394 for the Treatment of Primary Brain and CNS Malignancies

Retrieved on: 
Monday, March 20, 2023
Neurology, Biotechnology, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Other Health, China Biologic Products, Central nervous system, Drug development, ODD, Neoplasm, ESMO, Cancer, BRAF, Genomics, CNS, Trial of the century, V600, Malignancy, Patient, FORTE, Fore, Rare, European Society for Medical Oncology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Food, RAF, Pharmaceutical industry

FORE Biotherapeutics (FORE Bio) a precision stage oncology company dedicated to developing innovative treatments that provide a better outcome for cancer patients announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead program, FORE8394, for the treatment of primary brain and central nervous system (CNS) malignancies.

Key Points: 
  • FORE Biotherapeutics (FORE Bio) a precision stage oncology company dedicated to developing innovative treatments that provide a better outcome for cancer patients announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead program, FORE8394, for the treatment of primary brain and central nervous system (CNS) malignancies.
  • This is the first orphan drug designation received by FORE Bio and the FORE8394 program.
  • "The receipt of Orphan Drug Designation is another important regulatory achievement that reinforces the FDA's recognition of the potential of FORE8394 to improve clinical outcomes in patients with BRAF-altered brain tumors,” said Stacie Shepherd, M.D., Ph.D., Chief Medical Officer of Fore Biotherapeutics.
  • Orphan Drug Designation is granted to drugs or biological products for the treatment of rare diseases or conditions that impact fewer than 200,000 people in the United States.

Fore Biotherapeutics Announces First Patient Dosed in Global Phase 2 Trial Evaluating FORE8394 in BRAF-Mutated Solid and Brain Tumors

Retrieved on: 
Thursday, February 23, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, FORTE, Safety, ESMO, HIV, Central nervous system, Cancer, European Society for Medical Oncology, MAPK, BRAF, FDA, Patient, Toxic encephalopathy, CNS, Cobicistat, Neoplasm, Pharmaceutical industry, MD

The FORTE master protocol trial builds upon the design and interim data of the ongoing Phase 1/2a clinical trial evaluating FORE8394 in advanced solid and CNS tumors with BRAF alterations.

Key Points: 
  • The FORTE master protocol trial builds upon the design and interim data of the ongoing Phase 1/2a clinical trial evaluating FORE8394 in advanced solid and CNS tumors with BRAF alterations.
  • “We are thrilled to have initiated our global Phase 2 trial of FORE8394 in patients with BRAF-mutated tumors who have previously received available treatments and are now in need of alternative therapies,” said Stacie Shepherd, MD, PhD., Chief Medical Officer of Fore Biotherapeutics.
  • The company previously announced interim data from the ongoing Phase 1/2a clinical trial evaluating FORE8394 in advanced solid and CNS tumors with activating BRAF alterations, providing evidence of durable anti-tumor activity in patients with BRAF-mutated (V600+) cancers.
  • Mature data from the Phase 1/2a clinical trial are expected in mid-2023.

Tattoo Artist Dillon Forte Opens Tattoo Ranch

Retrieved on: 
Wednesday, February 8, 2023
Men's Health, Health, FORTE, Inked (magazine), Tattoo, Kehlani, Imagine Dragons, Usher, Blackwork, TMZ, Tattoo artist, Entertainment Tonight, Interior design, Forte

AUSTIN, Texas, Feb. 8, 2023 /PRNewswire/ -- Austin based Tattoo Artist and entrepreneur Dillon Forte has announced the opening of his ambitious new "Tattoo Ranch" in Wimberley. Located just outside of Austin, his new FORTE ATX studio location caters to both locals and traveling clients looking for an elevated experience in tattooing. The 5 acre + space includes a beautiful, spacious new studio for tattoo clients and also is the new home of Forte Tattoo Tech, a growing line of eco-friendly tattoo products.

Key Points: 
  • The multi-talented tattooer, artist and entrepreneur opens his tattoo ranch just outside of Austin in Wimberley, TX.
  • AUSTIN, Texas, Feb. 8, 2023 /PRNewswire/ -- Austin based Tattoo Artist and entrepreneur Dillon Forte has announced the opening of his ambitious new "Tattoo Ranch" in Wimberley.
  • The 5 acre + space includes a beautiful, spacious new studio for tattoo clients and also is the new home of Forte Tattoo Tech , a growing line of eco-friendly tattoo products.
  • The Tattoo Ranch will be used to host some of Forte's upcoming events and plans that include events for the tattoo industry, FORTE art galleries and even spiritual retreats.

CloudMoyo Ranks #1 in Top 100 Companies to Work For 2022 by Seattle Business Magazine

Retrieved on: 
Thursday, January 12, 2023
Technology, Engineering, Security, Manufacturing, Software, Networks, Internet, Data Management, Artificial Intelligence, Partner, Community, Respect, Heart, Environment, FORTE, Openness, Family, Organization, Growth, Financial Times and McKinsey Business Book of the Year Award, Workforce, Pacific Northwest, Live Company Group, Microsoft, Life, Responsibility, Fairness, Icertis, Business, Management

For four years in a row, CloudMoyo has consistently ranked among the top companies on this annual list, beginning in 2019 and now again in 2022.

Key Points: 
  • For four years in a row, CloudMoyo has consistently ranked among the top companies on this annual list, beginning in 2019 and now again in 2022.
  • Thanks to the hard work of its employees and continued efforts to build a truly employee-centric culture, CloudMoyo claimed the number-one spot in Washington’s Top 100 Companies to Work For in 2022.
  • CloudMoyo continued to deliver high-value solutions and services to its customers through all the ups and downs of 2022.
  • The annual 100 Best Companies to Work For (currently in its 33rd year) was created by Seattle Business Magazine and its partner, the Best Companies Group.

Icertis Places First in Washington's 100 Best Companies to Work For

Retrieved on: 
Tuesday, January 10, 2023
Respect, Commitment, Newsweek, FORTE, Gold, Diversity, Organization, Workforce, Live Company Group, Icertis, Growth, CLM, Philosophy, Culture, Capital punishment, Openness, Management

BELLEVUE, Wash., Jan. 10, 2023 /PRNewswire/ -- Icertis, the contract intelligence company that pushes the boundaries of what's possible with contract lifecycle management (CLM), today announced that it has been named a Top 100 Company to Work For by Seattle Business Magazine for the sixth consecutive year. Icertis ranked #1 among large companies on the prestigious 2022 list.

Key Points: 
  • The annual 100 Best Companies to Work For initiative identifies, recognizes, and honors the best employers in Washington.
  • Now in its 33rd year, Seattle Business Magazine and its research partner, the Best Companies Group, identify 100 companies in several categories that benefit the area's economy, workforce, and fellow businesses.
  • Qualifying companies across Washington entered the two-part survey process to determine "Washington's 100 Best Companies to Work For," actively engaging in:
    Evaluations focused on each nominated Company's workplace policies, practices, philosophy, systems, and demographics.
  • Icertis celebrates six consecutive years of ranking in the 100 Best Companies to Work for List.

SHRM National President & CEO to Keynote GOSHRM's Inaugural Mental Health Forum, January 24; GOSHRM Wins Two Awards for Community Impact on Opioid Crisis

Retrieved on: 
Tuesday, January 10, 2023
Well, Certification, Mental health, SHRM, Drug, FORTE, Human resources, CDC, Opioid, Organization, Forum, Workforce, MBA, Convention center, COVID-19, Mental, CareerSource Central Florida, Society for Human Resource Management, NAMI, GuideWell, Centers for Disease Control and Prevention, Conference, McGee, CSCF, Workplace, Community, HR, PHR, International Center, Medicine, Management, Addiction, Central Florida

ORLANDO, Fla., Jan. 10, 2023 /PRNewswire-PRWeb/ -- The Greater Orlando Society for Human Resource Management (GOSHRM) will host its first Mental Health Forum on Tuesday, January 24 at the Wyndham Orlando Resort and Conference Center in Kissimmee, FL. The Forum is "A Well-being Gut Check" for HR and medical professionals seeking best practices to tackle mental health challenges in today's stressful, post-pandemic workplace.

Key Points: 
  • GOSHRM's goal in presenting the Mental Health Forum is to provide increased awareness and support for mental health concerns plaguing the current workforce.
  • "There is a real hesitancy among the HR community to talk openly about these issues," said GOSHRM President, Pamela J. McGee, SHRM-SCP, PHR, MBA.
  • "Our Mental Health Forum is designed to help break the silence and create a workplace culture that supports those who struggle."
  • During his Keynote address, SHRM President and CEO, Johnny C. Taylor, Jr., SHRM-SCP, will talk about "Workplace Culture: Caring About the Whole Self."

Forte Minerals Appoints New Independent Director

Retrieved on: 
Friday, December 2, 2022
COVID-19, AMAX, Mining, University, Copper, Canadian Securities Exchange, Senior, Gold, Retirement, Multimedia, FORTE, CSE, Oil, Security (finance), Forte, Geology

VANCOUVER, BC, Dec. 2, 2022 /PRNewswire/ - Forte Minerals Corp. ("Forte" or the "Company") (CSE: CUAU) (OTQB: FOMNF) (Frankfurt: 2OA)is pleased to announce the appointment of Mr. Richard Leveille to the Company's board of directors, bringing it to a total of five members.

Key Points: 
  • VANCOUVER, BC, Dec. 2, 2022 /PRNewswire/ - Forte Minerals Corp. ("Forte" or the "Company") (CSE: CUAU) (OTQB: FOMNF) (Frankfurt: 2OA)is pleased to announce the appointment of Mr. Richard Leveille to the Company's board of directors, bringing it to a total of five members.
  • His work experience progressed through companies such as AMAX, Kennecott, Rio Tinto, and Phelps Dodge.
  • Forte is pleased to welcome Mr. Richard Leveille to the team.
  • The Company has granted Mr. Richard Leveille 250,000 stock options with an exercise price of $0.20, exercisable for five years.

Pucarini Regional Follow-up Program Yields

Retrieved on: 
Wednesday, September 21, 2022
ASTER, Argillic alteration, COVID-19, Propylitic alteration, NWC, NE, Knowledge, FORTE, Company, News, Gold, Forward-looking statement, Program, Canadian Securities Exchange, National Instrument 43-101, Qualified person (European Union), CEO, CSE, Anomaly, Forte, Collection, Manganese, Bismuth, Zinc, Multimedia, National instrument, Soil, Mining, Iron ore, Rare-earth element, Uranium, Copper, BC, NW

Pursuant to our press release on April 20th, 2022 , an extensive regional mapping and sampling exploration program was launched and successfully executed to follow-up on 10 satellite targets in the district surrounding the Pucarini epithermal gold project.

Key Points: 
  • Pursuant to our press release on April 20th, 2022 , an extensive regional mapping and sampling exploration program was launched and successfully executed to follow-up on 10 satellite targets in the district surrounding the Pucarini epithermal gold project.
  • In late 2020, the Company staked 18 regional claims surrounding Pucarini, comprising 16,100 hectares.
  • The area selection was guided by knowledge gained at Pucarini to search for expressions of similar hydrothermal alteration signatures recognized in ASTER satellite imagery as part of the Company's regional generative exploration program.
  • One of these properties, named Pucarini North is immediately northwest and adjacent to Pucarini.

Forte Minerals Attends PDAC in Person

Retrieved on: 
Monday, June 13, 2022
Prospectors, Prospectors & Developers Association of Canada, Mining, Copper, CSE, Company, National Instrument 43-101, Canadian Securities Exchange, Forward-looking statement, FORTE, News, National instrument, Metro Toronto Convention Centre, Multimedia, COVID-19, PDAC, Qualified person (European Union), Association, Gold, Oil, Risk management, Forte, BC

VANCOUVER, BC, June 13, 2022 /PRNewswire/ - Forte Minerals Corp. ("Forte" or the "Company") (CSE: CUAU) (OTQB: FOMNF) (Frankfurt: 2OA),is pleased to announce that the company will be attending this year's Prospectors & Developers Association of Canada (PDAC) convention, taking place in person at the Metro Toronto Convention Centre on June 13-15, 2022.

Key Points: 
  • VANCOUVER, BC, June 13, 2022 /PRNewswire/ - Forte Minerals Corp. ("Forte" or the "Company") (CSE: CUAU) (OTQB: FOMNF) (Frankfurt: 2OA),is pleased to announce that the company will be attending this year's Prospectors & Developers Association of Canada (PDAC) convention, taking place in person at the Metro Toronto Convention Centre on June 13-15, 2022.
  • Forte is a newly listed junior mining exploration company with an attractive portfolio of high-quality copper and gold assets in Per.
  • The Company's portfolio combines early-stage and drill-ready targets with a historically discovered and drilled porphyry system that is strategically positioned for copper and gold resource development.
  • Watch the full video below to learn how Forte Minerals is well-positioned to thrive from prevailing copper prices.